IP Library Granted Patent US 7,459,142
Granted Patent B2
US 7,459,142 · App. 10/162,653 · Granted Dec 2, 2008

High viscosity embolizing compositions comprising prepolymers

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,459,142
App. No.
10/162,653
Granted
Dec 2, 2008
Kind
B2
Abstract

Disclosed are novel high viscosity compositions for embolizing blood vessels which comprise a biocompatible prepolymer and a contrast agent, and optionally a thickening agent and/or a biocompatible solvent. Also disclosed are methods for embolizing a vascular site by injecting high viscosity prepolymer compositions into said site. The disclosed compositions and methods are particularly well suited for the treatment of aneurysms.

Claims (22)

1. A method for embolizing a vascular site, said method comprising:

(a) selecting an embolic composition comprising

a cyanoacrylate prepolymer and/or partially reacted monomers and oligomers thereof;

a biocompatible contrast agent, in an amount capable of being monitored during injection; and

a thickening agent which is a polyacrylate polymer,

wherein the viscosity of said composition prior to injection is at least about 150 centistokes at 40° C.;

(b) transferring the embolic composition to a delivery catheter having a proximal end and a distal end, wherein the distal end of the delivery catheter is positioned at the vascular site to be embolized; and

(c) injecting the embolic composition into said vascular site in sufficient amounts to embolize said vascular site.

2. The method according to claim 1 , wherein the embolic composition further comprises a biocompatible solvent.

3. The method according to claim 1 , wherein said composition has a viscosity of at least 200 centistokes at 40° C.

4. The method according to claim 1 , wherein said composition has a viscosity of at least 500 centistokes at 40° C.

5. The method according to claim 1 , wherein said composition has a viscosity of from at least 500 to 5,000 centistokes at 40° C.

6. The method according to claim 1 , wherein said biocompatible contrast agent is a water insoluble contrast agent.

7. The method according to claim 6 , wherein said water insoluble contrast agent is selected from the group consisting of tantalum, tantalum oxide, tungsten, barium sulfate, gold, and platinum.

8. The method according to claim 7 , wherein said water insoluble contrast agent is tantalum.

9. The method according to claim 1 , wherein said biocompatible solvent is selected from the group consisting of ethyl lactate, dimethylsulfoxide, ethanol, acetone, ETHIODOL®, LIPIODOL®, iodinated poppy seed oil, iodinated soy bean oil, water, and hexamethyldisiloxane.

10. The method according to claim 1 , wherein said thickening agent is polymethyl methacrylate.

11. The method according to claim 1 , comprising an additional step of (a′) heating and mixing the embolic composition of step (a) to at least 40° C. to form a uniform suspension;

and wherein the material transferred in step (b) is the uniform suspension of step (a′).

12. The method according to claim 11 , wherein the composition transferred is maintained at a temperature above 40° C.

13. The method according to claim 1 , wherein, prior to the embolic composition being injected, a blood flow attenuating device is inserted immediately upstream the ejection port of said catheter.

14. The method according to claim 13 , wherein said blood flow attenuating device is an inflatable microballoon which permits both normal and attenuated blood flow depending upon whether the microballoon is deflated or inflated.

Assignments (8)
SECURITY INTEREST Recorded Jul 3, 2024
From: OMNISSA, LLC
To: UBS AG, STAMFORD BRANCH
Reel/Frame 068118/0004 →
CHANGE OF NAME Recorded Oct 30, 2017
From: TYCO HEALTHCARE GROUP LP
To: COVIDIEN LP
Reel/Frame 044321/0707 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2017
From: EV3 LLC
To: TYCO HEALTHCARE GROUP LP
Reel/Frame 044596/0835 →
CHANGE OF NAME Recorded Sep 28, 2017
From: EV3 INC.
To: EV3 LLC
Reel/Frame 044047/0456 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED AT REEL: 041504 FRAME: 0280. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Recorded Mar 30, 2017
From: MICRO THERAPEUTICS, INC.
To: EV3 INC.
Reel/Frame 042115/0105 →
MERGER Recorded Mar 8, 2017
From: MICRO THERAPEUTICS, INC.
To: EV3, INC.
Reel/Frame 041504/0280 →
CHANGE OF NAME Recorded Mar 8, 2017
From: EV3, INC.
To: EV3 LLC
Reel/Frame 041909/0720 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2008
From: GREFF, RICHARD J., PH.D
To: MICRO THERAPEUTICS, INC.
Reel/Frame 021757/0293 →